Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Nanomedicine Resolves Inflammation, Promotes Tissue Healing

Published: Wednesday, March 20, 2013
Last Updated: Wednesday, March 20, 2013
Bookmark and Share
A multicenter team of researchers has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving drugs to sites of tissue injury.

The nanoparticles, which were successfully tested in mice, have potential for the treatment of a wide array of diseases characterized by excessive inflammation, such as atherosclerosis. The study was published today in the online edition of the Proceedings of the National Academies of Science.

A key way in which the body protects itself against infection or injury is through acute inflammation. Ideally, this response first promotes the clearance of pathogens or damaged tissue; then, through a process called inflammation resolution, it clears cellular debris and inflammatory mediators and restores the tissue to its normal state. However, in many conditions, including heart disease, arthritis, and neurodegenerative diseases, the inflammatory process never resolves, leading to tissue damage.

“A variety of medications can be used to control inflammation. Such treatments, however, usually have significant side effects and dampen the positive aspects of the inflammatory response,” said co-senior author Ira Tabas, MD, PhD, the Richard J. Stock Professor, Department of Medicine, and professor of Pathology & Cell Biology (in Physiology and Cellular Biophysics) at CUMC. The other co-senior author is Omid Farokhzad, MD, Associate Professor of Anesthesiology and Director of Laboratory of Nanomedicine and Biomaterials at Brigham and Women’s Hospital (BWH).

To overcome these obstacles, the researchers incorporated two advances. First, based on an idea from co-lead author Gabrielle Fredman, PhD, a postdoctoral fellow at CUMC, they took advantage of a 24-amino-acid peptide, Ac2-26, which is derived from a naturally occurring protein mediator of inflammation resolution called annexin A1. Second, rather than simply inject the “naked” peptide into injured mice, they packaged the peptide into nanoparticles, designed by the BWH group, that are able to target drugs to sites of tissue injury. The nanoparticles were given this ability through the addition of two components: one that gives them stealthlike properties, enabling them to avoid detection and clearance by white blood cells and the liver; and a second that gives them the ability to target collagen IV, a protein found at sites of tissue injury.

Each nanoparticle is less than 100 nanometers in diameter, or 1/100,000th the diameter of a human hair.

The nanoparticles were tested in mice with peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen) or hind-limb ischemia-reperfusion injury (tissue damage caused when blood supply returns to tissue after a period of ischemia, or lack of oxygen). In the mice with peritonitis, intravenous administration of the Ac2-26-containing nanoparticles was significantly more effective at limiting recruitment of neutrophils (a type of inflammatory white blood cell) and at increasing the resolution of inflammation than was intravenous administration of naked Ac2-26. In mice with reperfusion injury, the nanoparticles reduced tissue damage in comparison with either of two types of control nanoparticles: those with a peptide in which the 24 amino acids were scrambled to render it biologically inactive and Ac2-26 nanoparticles without the collagen IV-targeting component.

“These targeted polymeric nanoparticles are capable at very small doses of stopping neutrophils, the most abundant form of white blood cells, from infiltrating sites of disease or injury,” said co-lead author Nazila Kamaly, PhD, a postdoctoral fellow at BWH. “This action stops the neutrophils from secreting further signaling molecules that can lead to a constant hyper-inflammatory state and further disease complications.”

“The beauty of this approach is that, unlike many other anti-inflammatory approaches, it takes advantage of nature’s own design for preventing inflammation-induced damage, which does not compromise host defense and promotes tissue repair,” said Dr. Tabas.

While the nanoparticles do spread to tissues throughout the body, they tend to concentrate in areas of inflammation. “In theory, this should allow physicians to use smaller-than-usual doses of medications and reduce unwanted side effects,” said Dr. Fredman.

The team is currently designing nanoparticles for the treatment of atherosclerosis. Preliminary studies show that the nanoparticles are capable of targeting atherosclerotic plaques.

The authors have filed a patent for targeted polymeric inflammation-resolving nanoparticles to treat a variety of chronic inflammatory diseases, including atherosclerosis, autoimmune disease, type 2 diabetes, and Alzheimer’s disease.

The paper is titled, “Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles.” The other contributors are Manikandan Subramanian (CUMC), Suresh Gadde (BWH), Aleksandar Pesic (BWH), Louis Cheung (BWH), Zahi Adel Fayad (Mount Sinai School of Medicine), and Robert Langer (Massachusetts Institute of Technology).

This research was supported by a Program of Excellence in Nanotechnology Award from the National Heart, Lung, and Blood Institute (HHSN268201000045), a grant from the National Institutes of Health (CA151884), and a David Koch–Prostate Cancer Foundation Awardin Nanotherapeutics.

In compliance with the Brigham and Women’s Hospital and Harvard Medical School institutional guidelines, Dr. Farokhzad discloses his financial interest in BIND Biosciences, Selecta Biosciences, and Blend Therapeutics, three biotechnology companies developing nanoparticle technologies for medical applications. BIND, Selecta and Blend did not support the research described above, and currently these companies have no rights to any technology or intellectual property developed as part of this research. BIND, Selecta, and Blend were founded by Drs. Farokhzad and Langer, who serve as members of the Boards of Directors and Scientific Advisory Boards.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
Friday, July 24, 2015
Neurons Controlling Appetite Made from Skin Cells
Cells provide individualized model for studying obesity and testing treatments.
Monday, March 02, 2015
Bone Stem Cells Shown To Regenerate Bone And Cartilage In Adult Mice
Cells could be exploited to treat osteoarthritis and osteoporosis.
Monday, January 19, 2015
Non-Gluten Proteins as Targets of Immune Response to Wheat in Celiac Disease
The results were reported online in the Journal of Proteome Research.
Thursday, December 18, 2014
Human Stem Cells Converted to Functional Lung Cells
Possibility of generating lung tissue for transplant using a patient’s own cells.
Thursday, December 05, 2013
New Link Between Obesity and Diabetes Found
Targeting a single enzyme that raises both sugar and insulin levels in the obese could prevent and treat diabetes.
Monday, November 25, 2013
Human Stem Cells Elucidate Mechanisms of Beta-Cell Failure in Diabetes
Mechanisms that impair insulin production in diabetes identified using a human stem cell model of Wolfram syndrome, a rare form of diabetes.
Thursday, November 14, 2013
Researchers Discover Cells that Restore Bladder’s Unique Lining
Finding that could lead to new ways to treat chronic bladder pain or to produce new tissue for patients with damaged bladders.
Tuesday, September 24, 2013
Trial Aims to Advance Prenatal Diagnosis of Genetic Defects
High-risk pregnant women being recruited for research on chromosomal abnormalities and incidence of birth defects, developmental delays.
Thursday, August 22, 2013
Is There a Role for Vitamins in Cancer Prevention?
According to recent national surveys, approximately 40 percent of U.S. adults take multivitamins/multiminerals.
Monday, August 12, 2013
DNA Robots Find and Tag Blood Cells
Researchers have created a fleet of molecular “robots” that can home in on specific human cells and mark them for drug therapy or destruction.
Thursday, August 08, 2013
Study Reveals Genes That Drive Brain Cancer
About 15 percent of glioblastoma patients could receive personalized treatment with drugs currently used in other cancers.
Tuesday, August 06, 2013
Key Molecular Pathways Leading to Alzheimer’s Identified
Research approach highlights potential therapeutic targets.
Thursday, July 25, 2013
New Genetic Cause of Pulmonary Hypertension Identified
Study finds druggable target for rare fatal lung disease.
Thursday, July 25, 2013
Mutation Linked to Congenital Urinary Tract Defects
Findings point to new diagnostic category.
Thursday, July 18, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!